Cytotec (Misoprostol): Clinical Overview
Cytotec (misoprostol) is a synthetic prostaglandin E1 analog originally FDA-approved for prevention of NSAID-induced gastric ulcers, but now extensively used off-label in obstetrics and gynecology for medication abortion, labor induction, and postpartum hemorrhage management.
FDA-Approved Indication
NSAID-Induced Ulcer Prevention
- Approved dosing: 200 mcg four times daily with food 1
- Alternative regimens: 200 mcg twice or three times daily provides substantial protection with better tolerability than four-times-daily dosing 2
- The twice-daily and three-times-daily regimens show significantly lower withdrawal rates (12% each) compared to four-times-daily dosing (20%) 2
Primary Off-Label Uses in Obstetrics
Medication Abortion (14-27 weeks gestation)
The combination of mifepristone 200 mg followed by misoprostol is the most effective regimen for second-trimester medication abortion 3. Key protocols:
Combination regimen (preferred):
- Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400 mcg sublingually or buccally every 3 hours 3
- Success rate: 98% complete expulsion by 48 hours 3
- Mean time to expulsion: 5.8-8 hours 3
- Continue dosing until complete expulsion; most patients need ≤6 doses 3
Misoprostol-only regimen (when mifepristone unavailable):
- 400 mcg vaginally every 3-6 hours (up to 5 doses) 3, 4
- Less effective than combination: 90% vs 98% success at 48 hours 3
- Mean time to expulsion: 11-12 hours 3
Labor Induction
For labor induction with unfavorable cervix, vaginal dinoprostone (10 mg insert) demonstrates superior vaginal delivery rates (73.6%) compared to misoprostol (50.9%), though misoprostol shortens induction-to-delivery time 5.
Misoprostol regimens for labor induction:
- Vaginal: 25 mcg every 4-6 hours 6, 7
- Oral: 25 mcg every 2-4 hours 8
- 85-89% achieve delivery within 48 hours 6, 7
Critical caveat: Misoprostol for labor induction carries increased risks of cesarean section (particularly in nulliparous women), uterine hyperstimulation, and fetal complications compared to dinoprostone 5, 8.
Postpartum Hemorrhage
- Prevention: 600 mcg oral dose 9
- Treatment: 800 mcg sublingual dose appears effective as first-line therapy 9
Contraindications (FDA Label)
Absolute contraindications 1:
- Pregnancy (when used for ulcer prevention) - Pregnancy Category X
- Known hypersensitivity to prostaglandins
Obstetric contraindications for labor induction/augmentation 1:
- Prior uterine surgery including cesarean delivery (increased uterine rupture risk)
- Grand multiparity
- Non-reassuring fetal status
- Abnormal fetal positioning
Adverse Effects
Common Side Effects 1:
- Gastrointestinal: Diarrhea (13-40%, dose-dependent), abdominal pain (7-20%), nausea (3.2%), flatulence (2.9%)
- Diarrhea typically develops within 13 days, self-limiting within 8 days, but causes discontinuation in 2% 1
- Gynecological: Spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%)
Obstetric Adverse Effects 1:
- Uterine hyperstimulation progressing to tetany
- Uterine rupture (requiring surgical repair, hysterectomy)
- Severe genital bleeding, retained placenta
- Fetal bradycardia, meconium passage
- Increased cesarean delivery rates with higher doses
Serious but Rare 1:
- Profound diarrhea with severe dehydration
- Cardiovascular events (MI, CVA, thromboembolism)
- Anaphylaxis
Key Clinical Pearls
Dosing varies dramatically by indication - from 25 mcg for labor induction to 800 mcg for postpartum hemorrhage treatment 10, 11, 9. Using incorrect doses is dangerous: too low is ineffective, too high causes maternal and fetal harm.
Minimize diarrhea by administering with food and at bedtime, avoiding magnesium-containing antacids 1.
Monitor high-risk patients carefully: Those with inflammatory bowel disease or conditions where dehydration would be dangerous require close observation 1.
Advantages over other prostaglandins: Misoprostol is inexpensive, stable at room temperature (no refrigeration needed), and widely available - making it particularly valuable in resource-limited settings 11, 9.
Teratogenic risk: Misoprostol causes skull defects, cranial nerve palsies, facial malformations, and limb defects when pregnancy continues after failed abortion attempts 1. Women of childbearing age using it for ulcer prevention must have negative pregnancy test and use effective contraception.
Nursing mothers: Misoprostol is excreted in breast milk as the active metabolite misoprostol acid; exercise caution though no published adverse effects in infants 1.